Home  |  About the Book  |  Table of Contents  |  Search  |  Archive  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abrahm, J. L.
Right arrow Articles by Rades, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Abrahm, J. L.
Right arrow Articles by Rades, D.

Personalized Treatment for Malignant Spinal Cord Compression: A Multidisciplinary Approach

Janet L. Abrahm, MD, Roy A. Patchell, MD, and Dirk Rades, MD

From the Dana-Farber Cancer Institute (Dr. Abrahm), the University of Kentucky Medical Center (Dr. Patchell), and the University Hospital Schleswig-Holstein (Dr. Rades)

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Address reprint requests to Janet L. Abrahm, MD, Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, 44 Binney Street, SW 420, Boston, MA 02115; e-mail: jabrahm{at}partners.org

Overview: Each year, 12,700 patients with cancer develop malignant spinal cord compression (MSCC), putting them at risk for pain, paraparesis or paralysis, incontinence, and institutionalization.1 Breast, prostate, and lung cancer each account for 15% to 20% of cases; non-Hodgkin's lymphoma, myeloma, and renal cell carcinoma each account for 5% to 10%, and the rest are primarily attributable to colorectal cancer, cancer of unknown primary, and sarcoma.2,3